期刊
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
卷 329, 期 3, 页码 995-1005出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/jpet.109.152090
关键词
-
The Smoothened receptor (Smo) mediates hedgehog (Hh) signaling critical for development, cell growth, and migration, as well as stem cell maintenance. Aberrant Hh signaling pathway activation has been implicated in a variety of cancers, and small-molecule antagonists of Smo have entered human clinical trials for the treatment of cancer. Here, we report the biochemical characterization of allosteric interactions of agonists and antagonists for Smo. Binding of two radioligands, [H-3]3-chloro-N-[trans-4-(methylamino) cyclohexyl]-N-{[3-(4-pyridinyl)phenyl] methyl}-1-benzothiophene-2-carboxamide (SAG-1.3) (agonist) and [H-3]cyclopamine (antagonist), was characterized using human Smo expressed in human embryonic kidney 293F membranes. We observed full displacement of [H-3]cyclopamine by all Smo agonist and antagonist ligands examined. N-[(1E)-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-yl)methylidene]-4-(phenylmethyl)-1-piperazinamine (SANT-1), an antagonist, did not fully inhibit the binding of [H-3]SAG-1.3. In a functional cell-based beta-lactamase reporter gene assay, SANT-1 and N-[3(1H-benzimidazol-2-yl)-4-chlorophenyl]-3,4,5-tris(ethyloxy)benzamide (SANT-2) fully inhibited 3-chloro-4,7-difluoro-N[trans-4-(methylamino) cyclohexyl]- N-{[3-(4-pyridinyl) phenyl] methyl}1-benzothiophene-2-carboxamide (SAG-1.5)-induced Hh pathway activation. Detailed Schild-type radioligand binding analysis with [H-3]SAG-1.3 revealed that two structurally distinct Smoothened receptor antagonists, SANT-1 and SANT-2, bound in a manner consistent with that of allosteric modulation. Our mechanism of action characterization of radioligand binding to Smo combined with functional data provides a better understanding of small-molecule interactions with Smo and their influence on the Hh pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据